Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

c-erbB-2 expression in primary breast cancer.

E Tagliabue1, S Ménard, J F Robertson

  • 1Division of Experimental Oncology E, Istituto Nazionale Tumori, Milan, Italy. tagliabue@istitutotumori.mi.it

The International Journal of Biological Markers
|June 15, 1999
PubMed
Summary

c-erbB-2 oncoprotein overexpression in breast cancer has prognostic implications, particularly in lymph node-positive patients. Its role in lymph node-negative disease and response to therapies like anthracyclines and taxanes requires further investigation.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Obesity effect on newly diagnosed and recurrent post-ablation atrial fibrillation: a systematic review and meta-analysis.

Journal of endocrinological investigation·2023
Same author

Innovative therapy, monoclonal antibodies, and beyond: Highlights from the eighth annual meeting.

Cytokine & growth factor reviews·2018
Same author

Pregnancy outcome after rituximab treatment before conception in patients affected by severe pemphigus vulgaris/superficialis.

Journal of the European Academy of Dermatology and Venereology : JEADV·2017
Same author

Pathobiological implications of the d16HER2 splice variant for stemness and aggressiveness of HER2-positive breast cancer.

Oncogene·2016
Same author

MC1R gene variants and non-melanoma skin cancer: a pooled-analysis from the M-SKIP project.

British journal of cancer·2015
Same author

Prognostic role of tumor size in T1 HER2-positive breast cancers treated with adjuvant trastuzumab.

Annals of oncology : official journal of the European Society for Medical Oncology·2014

Area of Science:

  • Oncology
  • Molecular Biology
  • Cancer Research

Background:

  • c-erbB-2 is an oncoprotein overexpressed in up to 40% of primary breast cancers.
  • Overexpression is a known poor prognostic factor in lymph node-positive breast cancer patients.
  • The prognostic significance in lymph node-negative disease remains debated.

Purpose of the Study:

  • To review the prognostic significance of c-erbB-2 overexpression in breast cancer.
  • To explore the correlation between c-erbB-2 and treatment response, including hormone therapy, alkylating agents, anthracyclines, and taxanes.
  • To examine changes in c-erbB-2 expression during therapy.

Main Methods:

  • Literature review of studies on c-erbB-2 overexpression in breast cancer.
  • Analysis of correlations between c-erbB-2 status and prognostic factors (lymph node status, estrogen receptor).

Related Experiment Videos

  • Evaluation of treatment response data (alkylating agents, anthracyclines, taxanes, tamoxifen, chemotherapy) in relation to c-erbB-2 expression.

    • Main Results:

    • c-erbB-2 overexpression correlates with absence of estrogen receptor expression.
    • Association between c-erbB-2 overexpression and resistance to alkylating agents.
    • Anthracyclines may have greater therapeutic effect in c-erbB-2-positive disease, potentially dose-sensitive.
    • Therapeutic effect of anthracyclines is reduced in c-erbB-2-negative disease.
    • Data on taxanes and c-erbB-2 is inconclusive, with potential correlation for paclitaxel needing confirmation.
    • Few studies show no significant change in c-erbB-2 on tamoxifen or chemotherapy.

    Conclusions:

    • c-erbB-2 overexpression has established prognostic value in lymph node-positive breast cancer.
    • Its prognostic role in lymph node-negative disease requires further clarification.
    • Evidence suggests differential response to anthracyclines based on c-erbB-2 status.
    • Further research is needed to confirm the role of taxanes and understand c-erbB-2 dynamics during therapy.